DGAP-News
Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
DGAP-News: Evotec SE / Key word(s): Miscellaneous |
Germany and France, 06. July 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader
in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial
Resistance (AMR).
The resulting company, Aurobac Therapeutics SAS, will combine the best-of-best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to
cure. The aspiration is to succeed in the fight against AMR, which is a major public health threat. Having routine surgery such as caesarean sections or hip replacements may become life
threatening, and complications from common diseases such as diabetes and injuries or cuts will become harder to manage because of AMR.
Werner Lanthaler, CEO of Evotec, said: “The grim prospect of a post-antibiotic era has many causes but only one solution: The development of new, targeted, and effective antimicrobial
therapies. We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMérieux, to combine our complementary strengths. By leveraging Evotec’s multimodality
approach to infectious diseases, we are confident that Aurobac will be able to generate much-needed progress to tackle the global challenge of AMR”.
“The rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR – is indeed a looming global crisis,” added Michel Pairet, Head of Boehringer Ingelheim’s Innovation
unit and Member of the Board of Managing Directors. “Antibiotic resistance kills about 1.27 million people globally every year1 and it has been estimated that by 2050, as many as
10 million worldwide deaths could result from AMR2, making it potentially deadlier than cancer.”